AU702801B2 - Therapeutic use of D-threo-methylphenidate - Google Patents
Therapeutic use of D-threo-methylphenidate Download PDFInfo
- Publication number
- AU702801B2 AU702801B2 AU64660/96A AU6466096A AU702801B2 AU 702801 B2 AU702801 B2 AU 702801B2 AU 64660/96 A AU64660/96 A AU 64660/96A AU 6466096 A AU6466096 A AU 6466096A AU 702801 B2 AU702801 B2 AU 702801B2
- Authority
- AU
- Australia
- Prior art keywords
- methylphenidate
- patient
- treatment
- threo
- susceptible
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- DUGOZIWVEXMGBE-CHWSQXEVSA-N dexmethylphenidate Chemical compound C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-CHWSQXEVSA-N 0.000 title claims description 7
- 229960001042 dexmethylphenidate Drugs 0.000 title claims description 7
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 229960001344 methylphenidate Drugs 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 18
- 208000027700 hepatic dysfunction Diseases 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 11
- 210000004185 liver Anatomy 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 230000005976 liver dysfunction Effects 0.000 claims description 4
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 claims description 3
- 206010067948 Compulsive shopping Diseases 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 201000003631 narcolepsy Diseases 0.000 claims description 3
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims description 2
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims description 2
- 206010067125 Liver injury Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 230000008818 liver damage Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 108010052832 Cytochromes Proteins 0.000 claims 1
- 102000018832 Cytochromes Human genes 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 125000003192 dTMP group Chemical group 0.000 description 16
- 238000009472 formulation Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 4
- 229960001033 methylphenidate hydrochloride Drugs 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 230000001055 chewing effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940125368 controlled substance Drugs 0.000 description 2
- 239000000599 controlled substance Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- DUGOZIWVEXMGBE-STQMWFEESA-N methyl (S)-phenyl[(S)-piperidin-2-yl]acetate Chemical compound C([C@H]1[C@@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-STQMWFEESA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002294 pubertal effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Description
WO 97/03672 PCT/GB96/01689 1 THERAPEUTIC USE OF d-threo-METHYLPHENIDATE Field of the Invention This invention relates to new therapeutic uses of d-threo-methylphenidate (abbreviated herein as dtmp).
Background or the Invention Methylphenidate is a known drug. It is used primarily to treat hyperactive children. It may have to be administered over a prolonged period of time, and is a controlled substance.
Methylphenidate is a chiral molecule. The properties of the enantiomers have been investigated to some extent, although the drug is still administered as the racemate.
It is generaly thought that dtmp is the active material, and that its antipode (ltmp) is metabolised more rapidly.
Methylphenidate is often administered in a sustainedrelease formulation. For example, a coated tablet comprising racemic methylphenidate is administered, with a view to maintaining a therapeutically-effective level of the drug. This formulation does not always provide a reproducible or a sustained effect.
Roberts et al, Life Sci. 55:269-281 (1994), found that racemic methylphenidate caused hepatic dysfunction in the mouse, manifest as elevated liver enzyme levels and/or coagulative necrosis, on morphological investigation of the liver. Also, the National Toxicity Programme (NTP TR439) of the USA recently (1995) found that racemic methylphenidate caused, in the mouse, hepatocellular and centri-lobular hypertrophy, formation of foci of damaged cells and hepatic tumours.
Mehta et al, J. Clin. Gastroenterol. 6:149-151 (1984), report hepatic dysfunction due to intravenous abuse of methylphenidate hydrochloride. Goodman, New York State Journal of Medicine 72:2339-40 (15 September 1972), reports hepatoxicity due to methylphenidate hydrochloride. Stecyk et al, Annals of Emergency Medicine 14:597/113-599/115 (6 June 1985), report multiple organ failure resulting from intravenous abuse of methylphenidate hydrochloride.
1. Summary of the Invention This invention is based on the discovery that dtmp can satisfactorily be used to treat human patients exhibiting or susceptible to hepatic dysfunction, or to reduce the likelihood of such symptoms occurring, dtmnp may also be used instead of the racemate in therapy involving the use of other drugs that have effects likely to be exacerbated by use of the racemate. Such effects may include hepatic dysfunction. The patient may be an adult, e.g. in the treatment of compulsive shopping disorder or narcolepsy, or a child, e.g. a pre-pubertal child suffering from attention-deficit hyperactivity disorder (which, for the purposes of this specification, includes attention-deficit disorder).
The discovery is based on the finding that, in an animal model, dtmp is suprisingly less hepatotoxic than racemic methylphenidate.
~Accordingly in a first aspect, the present invention provides a method 15 for the treatment of a human patient having a condition susceptible to treatment with methylphenidate, and wherein the patient exhibits or is *:.susceptible to hepatic dysfunction, which includes the administration of d-threo-methylphenidate substantially free of 1-threo-methylphenidate.
In a second aspect, the present invention provides a method for the treatment of a human patient having a condition susceptible to treatment with methylphenidate, wherein the patient is or has been exposed to circumstances that cause, or render the patient susceptible to, hepatic dysfunction, which includes the administration of d-thr'eo-methylphenidate substantially free of 1-thru'eo-methylphenidate.
In one embodiment of both aspects of the present invention, the patient has previously undergone, or is simultaneously undergoing, administration of a therapeutic agent that may cause or render the patient susceptible to hepatic dysfunction.
In a further embodiment of the aspects of the present invention, the therapeutic agent is racemic methylphenidate.
In still a further embodiment of both aspects of the invention, the patient has previously, or is simultaneously, taking a drug of abuse known to cause liver dysfunction or damage, including alcohol or ecstasy.
t; jt f
A
y In another embodiment of both aspects of the invention, the patient has abnormal levels of at least one liver enzyme.
In yet a further embodiment of both aspects of the invention, the liver enzyme is CYP2D6 or another P 45 0 cytochrone enzyme.
In another embodiment of both aspects of the invention, the condition is selected from depression, compulsive shopping disorder, narcolepsy, insomnia and attention-deficit hyperactivity disorder.
In a third aspect of the invention, there is provided a product containing d-threo-methylphenidate substantially free of l-threomethylphenidate, and a therapeutic agent that may cause or render the patient susceptible to hepatic dysfunction, as a combined preparation when used in simultaneous, separate or sequential treatment of a condition susceptible to treatment with methylphenidate and a condition susceptible to treatment with said therapeutic agent.
Description of the Invention The dtmp that is used in this invention is substantially free of Itmp, e.g. in an enantioneric excess (ee) of at least 70%, preferably at least and more preferably at least 95%. The dtmp may be substantially enantiopure. It may be used in the form of any suitable salt, e.g. the hydrochloride.
The dtmp may be administered by the same means as is known for racemic methylphenidate, in a sustained-release formulation, o.g. a coated tablet. It may be administered in any other conventional sustained-release formulation, via any suitable route of administration. Conventional dosing parameters may be adopted, i.e. those which are known to or adapted to the practice of those skilled in the art. For example, the daily dosage of dtmp may be 5 to 60 mg, but will be chosen according to the age, weight and health of the subject, and other factors that are routinely considered by the man skilled in the art.
Other advantages of the use of dtmp may include the reduction of exposure to a controlled substance, reduced i WO 97/03672 PCT/G B96/01689 3 side-effects (which include anorexia, insomnia, stomach ache and headache), reduced abuse potential, reduced C a reduced level of active material even when chewed, reduced patient variability, reduced interaction with ltmp or other drugs, and less variability between fed and fasted subjects.
By controlling the nature of the formulation, it is possible to control dissolution in vitro, and thus match or exceed the US National Formulary (NF) drug release profile for methylphenidate hydrochloride. Further, when administered to a healthy subject, a serum level of dtmp can be attained that is at least 50% of Cx over a period of at least 8 hours, e.g. 8-16, 8-12 or 8-10 hours. Thus, for example, a shorter release period may be preferred or a different period before the serum level drops below a different proportion of Cmx.
The serum level may be also controlled so that it remains high during the day, after taking a dosage in the morning, and is reduced in the evening, before it can have any undesirable effect on sleeping patterns.
A formulation of the invention may be a unit dosage such as a tablet, capsule or suspension. A sustainedrelease formulation may be in matrix, coating, reservoir, osmotic, ion-exchange or density exchange form. It may comprise a soluble polymer coating which is dissolved or eroded, after administration. Alternatively, there may be an insoluble coating, e.g. of a polymer, through which the active ingredient permeates, as from a reservoir, diffuses, e.g. through a porous matrix, or undergoes osmotic exchange. A further option for a sustained-release formulation involves density exchange, in the case where the formulation alters on administration, e.g. from microparticles to a gel, so that the active ingredient diffuses or permeates out. Ion-based resins may also be used, the active component being released by ionic exchange, and wherein the rate of release can be controlled by using cationic or anionic forms of the drug.
L- I WO 97/03672 PCT/GB96/01689 4 It is preferred to use a formulation in this invention that is resistant to chewing, e.g. micronised particles that are individually coated and which do not immediately release the active component on chewing, or possibly even actively discourage chewing by their consistency. Many effects, benefits etc. described herein apply also to formulations providing immediate release. The various effects etc. may be due to the use of dtmp and/or the absence of Itmp.
Various circumstances may cause hepatic dysfunction, or render a patient susceptible to such a problem. Such circumstances include the administration of a therapeutic agent in which liver dysfunction, is a side-effect, or the taking of drugs of abuse known to cause liver dysfunction, e.g. alcohol or ecstasy.
Hepatic dysfunction may be evident in terms of interference with enzyme function, or changes in the levels of certain enzymes such as alanine aminotransferase (ALT), or in terms of gross alterations such as cirrhosis or cancer of the liver. Hepatic dysfunction can be determined by the skilled man, as may be susceptibility or predisposition to such dysfunction.
Methylphenidate-Induced Hepatotoxitv in Mice Experiments were carried out to investigate the differing toxicity effects of dtmp and racemic methylphenidate characterised by elevated liver enzyme levels and instances of coagulative necrosis in the liver.
The procedures followed were as described in Roberts et al, supra.
Groups of 21 male mice of the Crl:CD-1(ICR)BR strain were given a single intraperitoneal dose of the compounds in a saline solution with an injection volume of 10 ml/kg body weight. The animals were housed in groups of three in polypropylene cages with a steel mesh floor in a single, exclusive room, air conditioned to provide a minimum of air changes/hour. Animal quarters were temperature and humidity controlled with a 12 hour light/dark cycle.
I
WO 97/03672 PCT/GB96/01689 Blood samples were obtained from all animals at 16 hours after dosing for determination of serum alanine aminotransferase (ALT) activity. The results are tabulated below.
Livers were removed 24 hours after: dosing and preserved in fixative of 10% neutral buffered formalin for histopathological examination. The livers were embedded in paraffin wax, sectioned at a nominal 5 Am, stained with haematoxylin and eosin, and examined using light microscopy. The results are tabulated below.
Compound Dose ALT Levels Coagulant _(mg/kg) (IU/L) Necrosis Control (water) 0 81 0 Racemate 75 185 2 dtmp 75 76 0 The results show that there is a marked beneficial effect of treatment with dtmp relative to treatment with racemic methylphenidate, in that plasma levels of the liver enzyme alanine aminotransferase were not increased. The histopathology data further support the finding that dtmp treatment has beneficial advantages over treatment with the racemate. Coagulant necrosis was detected in two animals out of 21 in the group receiving racemic methylphenidate, whereas there were no cases with dtmp. Thus, the results show a marked difference.
I a -r
Claims (9)
1. A method for the treatment of a human patient having a condition susceptible to treatment with methylphenidate, and wherein the patient exhibits or is susceptible to hepatic dysfunction, which includes the administration of d-thrzeo-methylphenidate substantially free of 1-threo- methylphenidate.
2. A method for the treatment of a human patient having a condition susceptible to treatment with methylphenidate, wherein the patient is or has been exposed to circumstances that cause, or render the patient susceptible to, hepatic dysfunction, which includes the administration of d-threo- methylphenidate substantially free of 1-threo- methylphenidate. 15
3. A method according to claim 1 or claim 2, wherein the patient has previously undergone, or is simultaneously undergoing, administration of a therapeutic agent that may S* cause or render the patient susceptible to hepatic dysfunction.
4. A method according to claim 3, wherein said therapeutic agent is racemic methylphenidate. 0.
5. A method according to claim 1 or claim 2, wherein the patient has previously, or is simultaneously, taking a drug of abuse known to cause liver dysfunction or damage, 25 including alcohol or ecstasy.
6. A method according to any preceding claim, wherein the patient has abnormal levels of at least one liver enzyme.
7. A method according to claim 6, wherein the at least one liver enzyme is CYP2D6 or another P50 cytochrome enzyme.
8. A method according to any preceding claim, wherein the condition is selected from depression, compulsive shopping disorder, narcolepsy, insomnia and attention-deficit hyperactivity disorder.
9. A product containing d-threo-methylphenidate substantially free of 1-threo-methylphenidate, and a therapeutic agent as defined in claim 3, as a combined -ji o I! I -P I preparation when used in simultaneous. separate or sequential treatment of a condition as defined in claim 1 or claim 2 and a condition susceptible to treatment with said therapeutic agent. Dated this seventh day of January 1999 CHI-ROSCIENCE LIMITED Patent Attorneys for the Applicant: F B RICE CO fit e II-I I b
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9514416 | 1995-07-14 | ||
| GBGB9514416.8A GB9514416D0 (en) | 1995-07-14 | 1995-07-14 | Therapeutic use |
| GBGB9605523.1A GB9605523D0 (en) | 1996-03-15 | 1996-03-15 | Therapeutic use |
| GB9605523 | 1996-03-15 | ||
| PCT/GB1996/001689 WO1997003672A1 (en) | 1995-07-14 | 1996-07-15 | THERAPEUTIC USE OF d-threo-METHYLPHENIDATE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6466096A AU6466096A (en) | 1997-02-18 |
| AU702801B2 true AU702801B2 (en) | 1999-03-04 |
Family
ID=26307400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU64660/96A Ceased AU702801B2 (en) | 1995-07-14 | 1996-07-15 | Therapeutic use of D-threo-methylphenidate |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0839038A1 (en) |
| JP (1) | JPH11509227A (en) |
| AU (1) | AU702801B2 (en) |
| CA (1) | CA2223629A1 (en) |
| WO (1) | WO1997003672A1 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5908850A (en) * | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US6355656B1 (en) | 1995-12-04 | 2002-03-12 | Celgene Corporation | Phenidate drug formulations having diminished abuse potential |
| US6486177B2 (en) | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
| US5733756A (en) * | 1996-01-05 | 1998-03-31 | Celgene Corporation | Lactams and processes for stereoselective enrichment of lactams, amides, and esters |
| US5922736A (en) * | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
| US6962997B1 (en) | 1997-05-22 | 2005-11-08 | Celgene Corporation | Process and intermediates for resolving piperidyl acetamide steroisomers |
| MXPA01004381A (en) | 1998-11-02 | 2005-09-08 | Elan Corp Plc | Multiparticulate modified release composition. |
| US6673367B1 (en) | 1998-12-17 | 2004-01-06 | Euro-Celtique, S.A. | Controlled/modified release oral methylphenidate formulations |
| US7083808B2 (en) | 1998-12-17 | 2006-08-01 | Euro-Celtique S.A. | Controlled/modified release oral methylphenidate formulations |
| US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| US6127385A (en) * | 1999-03-04 | 2000-10-03 | Pharmaquest Limited | Method of treating depression using l-threo-methylphenidate |
| US6395752B1 (en) * | 1999-03-04 | 2002-05-28 | Pharmaquest Limited | Method of treating depression using 1-threo-methylphenidate |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| KR100889069B1 (en) | 1999-10-29 | 2009-03-17 | 유로-셀티크 소시에떼 아노뉨 | Controlled release hydrocodone formulations |
| AU2738302A (en) | 2000-10-30 | 2002-05-15 | Euro Celtique Sa | Controlled release hydrocodone formulations |
| US6913768B2 (en) | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
| US20050239830A1 (en) * | 2004-04-26 | 2005-10-27 | Vikram Khetani | Methods of diminishing co-abuse potential |
| DK2036546T3 (en) | 2004-08-23 | 2018-12-17 | Pejo Iserlohn Heilmittel Und Diaet Gmbh & Co Kg | Psychostimulants containing a pharmaceutical composition |
| WO2011020032A2 (en) | 2009-08-13 | 2011-02-17 | Kudco Ireland, Ltd. | Pharmaceutical dosage form |
| CN105025883A (en) | 2013-03-29 | 2015-11-04 | 沃克哈特有限公司 | Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof |
| CA2936740C (en) | 2014-10-31 | 2017-10-10 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
-
1996
- 1996-07-15 AU AU64660/96A patent/AU702801B2/en not_active Ceased
- 1996-07-15 WO PCT/GB1996/001689 patent/WO1997003672A1/en not_active Ceased
- 1996-07-15 EP EP96924082A patent/EP0839038A1/en not_active Withdrawn
- 1996-07-15 CA CA002223629A patent/CA2223629A1/en not_active Abandoned
- 1996-07-15 JP JP9506411A patent/JPH11509227A/en not_active Ceased
Non-Patent Citations (3)
| Title |
|---|
| CLIN PHAR. & THERAPUTICS VOL 55 NO 3 MARCH 1993 AOYAMA ET AL * |
| J. PHAR. & EXPER. THER. VOL241 NO1 APRIL'87 PATRICK ET AL * |
| MOLE. PHARMACOLOGY, VOL 40 NO 1 JULY 1991, TYNDALE ET AL * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH11509227A (en) | 1999-08-17 |
| WO1997003672A1 (en) | 1997-02-06 |
| CA2223629A1 (en) | 1997-02-06 |
| AU6466096A (en) | 1997-02-18 |
| EP0839038A1 (en) | 1998-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU702801B2 (en) | Therapeutic use of D-threo-methylphenidate | |
| US5874090A (en) | Sustained-release formulation of methylphenidate | |
| AU708873B2 (en) | Composition comprising d-threo-methylphenidate and another drug | |
| US11103495B2 (en) | Methylphenidate extended release chewable tablet | |
| US9839619B2 (en) | Method for treating ADD or ADHD comprising administering amphetamine complexed with ion-exchange resin particles | |
| CN116712434A (en) | Methods of administering certain VMAT2 inhibitors | |
| US20150051192A1 (en) | Blocking of cue-induced drug reinstatement | |
| CN109069480A (en) | For treating the method and composition of illness relevant to epilepsy | |
| CA2218054C (en) | Solid compositions containing polyethylene oxide and an active ingredient | |
| Langer | Polymer implants for drug delivery in the brain | |
| JP2001502671A (en) | Sustained-release pharmaceutical composition of HMG-CoA reductase inhibitor fluvastatin | |
| JP5561885B2 (en) | A new formulation of mirtazapine | |
| US20080279930A1 (en) | Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof | |
| WO2005044238A1 (en) | Modified release solid dosage form of amphetamine salts | |
| Bender et al. | High-dose methotrexate with folinic acid rescue | |
| JP2003512311A (en) | Sustained release formulations for treating CNS mediated disorders | |
| AU634149B2 (en) | Pain-killer | |
| CA3172749A1 (en) | Pediatric formulation of tyrosine kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |